FDA Widens Screwworm Drug Options as US Cases Near 50

Three weeks after the first emergency nod for a screwworm drug went to a prescription-only product, the FDA opened the fight to over-the-counter competition. On September 3rd, the agency authorized Sergeant's Pet Care Products' Capstar and a generic from Ireland's Felix Pharmaceuticals to both prevent and treat New World screwworm in dogs and cats, no vet visit required.

FDA authorizes Capstar, generic nitenpyram for screwworm

The Food and Drug Administration granted emergency use authorization on September 3rd to Capstar (nitenpyram) tablets from Sergeant's Pet Care Products, and separately expanded an existing authorization covering a generic nitenpyram product from Felix Pharmaceuticals. Both drugs are now cleared to prevent and treat New World screwworm infestations in dogs, puppies, cats, and kittens weighing at least two pounds and at least four weeks old.

Felix Pharmaceuticals' generic version first received emergency clearance on June 11th for treatment only. Today's action extends that authorization to prevention, closing the gap with Capstar's broader clearance. Both products are sold over the counter in two tablet sizes, 11.4 mg and 57 mg, dosed by weight.

An emergency use authorization lets the FDA clear a product against a specific threat faster than a standard approval, requiring only a "reasonable belief" that benefits outweigh risks rather than the full efficacy record a standard approval demands.

Dr. Timothy Schell, director of FDA's Center for Veterinary Medicine, said the agency is "addressing a previously unmet need and giving pet owners and veterinarians important tools to protect dogs and cats from NWS infestations."

The authorizations arrive as confirmed New World screwworm infestations in Texas climbed to 47 as of August 26th, up from 32 in early July, according to a Houston Public Media tracker of state and federal case data.

Why an OTC screwworm drug pressures Zoetis's edge

Every screwworm authorization before this one required a prescription or ran through a government stockpile. Zoetis's Simparica Trio, cleared August 13th, treats dogs only and requires a veterinarian to write the script. Elanco's Negasunt and Tanidil, authorized in April for livestock, distribute exclusively through the USDA's Animal and Plant Health Inspection Service and never touch a retail shelf.

Capstar breaks that pattern. Sergeant's Pet Care Products has sold the drug over the counter for flea control for years, on the same pet-aisle shelves at Petco, Chewy, and Walmart where owners already buy it. Extending that existing retail footprint to screwworm means a pet owner in an affected county can now pick up a prevention treatment without a clinic visit, a meaningfully lower-friction path than anything Zoetis or Elanco currently offer.

For pet retailers and distributors, that changes the product-mix question. A vet-channel-only drug shows up nowhere on a retailer's planogram. An OTC nitenpyram tablet does, and one already carried under a household flea-control brand name requires no new vendor relationship to stock. Expect Petco, PetSmart, Tractor Supply, and Chewy to move quickly on merchandising a screwworm-specific SKU or shelf messaging, particularly in border-state stores.

Texas has already mandated NWS treatment before dogs cross certain lines within the state, a requirement that previously meant scheduling a vet visit for a prescription drug. An OTC option lets boarding facilities, rescue transporters, and everyday pet owners meet that requirement with a retail purchase instead, which should accelerate compliance in the border counties where the rule already applies.

The competitive read for Zoetis is more nuanced than losing share outright. Simparica Trio combines screwworm coverage with existing flea, tick, and heartworm protection in one chewable, a convenience argument OTC nitenpyram alone doesn't match. But Zoetis had effectively owned the "authorized drug" narrative in trade coverage for three weeks. That exclusivity on messaging, if not on mechanism, ends today.

The bigger structural signal is regulatory. FDA cleared Felix Pharmaceuticals' generic for treatment back in June and expanded it to prevention in roughly twelve weeks, then added a second, brand-name sponsor the same day. That cadence suggests the agency is treating New World screwworm emergency authorizations as a fast-moving, multi-sponsor track rather than a single-product exception, and that more manufacturers filing for their own EUAs is now the expected pattern rather than a surprise.

Whether other flea-and-tick brands file for EUAs next

The next signal to track is whether other household flea-and-tick brands follow Sergeant's into the category. Elanco, Boehringer Ingelheim, and Merck Animal Health all sell consumer-facing parasiticides with existing retail distribution, and none has filed for a screwworm EUA of its own yet. A second or third OTC entrant would confirm this is becoming a genuine multi-brand retail category rather than a one-off.

Case counts are the other variable worth tracking directly. Forty-seven confirmed Texas infestations as of late August is already up nearly 50% from early July, and any acceleration north or east would pull more retailers and distributors into stocking decisions they haven't had to make before.

Emergency authorizations also expire when the underlying public health declaration ends, not on a fixed date. If containment holds and the declaration lifts, today's OTC options could disappear from shelves as quickly as they arrived, leaving Zoetis's prescription drug as the only durable, non-emergency option in the category. If containment slips instead, expect OTC nitenpyram to become a standing category rather than a temporary one.

Source: FDA